MedTrace Logo

Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs

NCT05187767 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-11-08

No results posted yet for this study

Summary

The aim of the study is the early and non-invasive diagnosis of lung cancer in patients with pulmonary ground glass opacity. In particular, objective of the study is to evaluate the presence or absence of circulating tumor DNA (ctDNA) on the peripheral blood of patients with evidence of ground glass opacity(GGO) at CT scan and to evaluate the role that this can play in the diagnostic / therapeutic process. The ctDNA evaluation will be performed at the first radiological finding and subsequently correlated with the malignancy of the lesion based on the radiological / histological criteria regularly used in international protocols.

Secondary objective is the correlation, in patients with malignant GGO undergoing surgical treatment, of the ctDNA presence and tumor spread through the air spaces (STAS), and its correlation with local relapses.

Conditions

  • Lung Cancer
  • Spreading of Tumor
  • Circulating Tumor Cell

Interventions

DIAGNOSTIC_TEST

cf DNA and ct DNA

Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Marco Anile, MD · University of Roma La Sapienza

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-01-31
Completion
2024-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05187767 on ClinicalTrials.gov